CY1109929T1 - Φαρμακευτικη συνθεση η οποια περιεχει φενοφιμπρατη και μεθοδος για την παρασκευη της - Google Patents

Φαρμακευτικη συνθεση η οποια περιεχει φενοφιμπρατη και μεθοδος για την παρασκευη της

Info

Publication number
CY1109929T1
CY1109929T1 CY20091100684T CY091100684T CY1109929T1 CY 1109929 T1 CY1109929 T1 CY 1109929T1 CY 20091100684 T CY20091100684 T CY 20091100684T CY 091100684 T CY091100684 T CY 091100684T CY 1109929 T1 CY1109929 T1 CY 1109929T1
Authority
CY
Cyprus
Prior art keywords
fenofibrate
composition
composition containing
surfactant
active layer
Prior art date
Application number
CY20091100684T
Other languages
English (en)
Inventor
Bruno Criere
Pascal Suplie
Philippe Chenevier
Pascal Oury
Keith S Rotenberg
George Bobotas
Original Assignee
Ethypharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34422141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109929(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm filed Critical Ethypharm
Publication of CY1109929T1 publication Critical patent/CY1109929T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά στη χρήση μιας σύνθεσης φενοφιμπράτης η οποία περιέχει μικρονισμένη φενοφιμπράτη, μια επιφανειοδραστική ουσία και ένα συνδετικό μέσο που είναι παράγωγο της κυτταρίνης σαν πρόσθετο διαλυτοποίησης, ενώ η εν λόγω σύνθεση περιέχει μία ποσότητα φενοφιμπράτης μεγαλύτερη από ή ίση με 60% κατά βάρος, για την παρασκευή ενός φαρμάκου για την αντιμετώπιση υπερτριγλυκεριδαιμιών, υπερχοληστερολαιμιών ή υπερλιπιδαιμιών, ενώ μειώνει την επίδραση που έχει η τροφή στη βιοδιαθεσιμότητα της φενοφιμπράτης. Η εφεύρεση αφορά επίσης σε μια σύνθεση άμεσης αποδέσμευσης στη μορφή κόκκων που περιλαμβάνουν (α) έναν ουδέτερο πυρήνα (β) μια δραστική στοιβάδα, η οποία περιβάλλει τον πυρήνα και (γ) μια εξωτερική στοιβάδα όπου η προαναφερθείσα δραστική στοιβάδα περιλαμβάνει μικρονισμένη φενοφιμπράτη, μια επιφανειοδραστική ουσία και ένα συνδετικό μέσο που είναι παράγωγο της κυτταρίνης και όπου η εν λόγω σύνθεση έχει προφίλ διαλυτοποίησης λιγότερο του 10% στα 5 λεπτά και περισσότερο από 80% στα 20 λεπτά σύμφωνα με την Ευρωπαϊκή Φαρμακοποιία σε ένα μέσο διαλυτοποίησης που αποτελείται από νερό με 0.025Μ λαουρυλο θειικό νάτριο.
CY20091100684T 2003-10-03 2009-06-30 Φαρμακευτικη συνθεση η οποια περιεχει φενοφιμπρατη και μεθοδος για την παρασκευη της CY1109929T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/677,861 US7863331B2 (en) 1999-07-09 2003-10-03 Pharmaceutical composition containing fenofibrate and method for the preparation thereof
EP04769636A EP1667666B9 (en) 2003-10-03 2004-10-01 Pharmaceutical composition containing fenofibrate and method for the preparation thereof

Publications (1)

Publication Number Publication Date
CY1109929T1 true CY1109929T1 (el) 2014-09-10

Family

ID=34422141

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100684T CY1109929T1 (el) 2003-10-03 2009-06-30 Φαρμακευτικη συνθεση η οποια περιεχει φενοφιμπρατη και μεθοδος για την παρασκευη της

Country Status (23)

Country Link
US (2) US7863331B2 (el)
EP (2) EP1667666B9 (el)
JP (1) JP5490354B2 (el)
KR (1) KR101150235B1 (el)
CN (1) CN100544712C (el)
AT (1) ATE428408T1 (el)
AU (1) AU2004277757B2 (el)
BR (1) BRPI0414860B8 (el)
CA (1) CA2540235C (el)
CY (1) CY1109929T1 (el)
DE (1) DE602004020641D1 (el)
DK (1) DK1667666T3 (el)
ES (1) ES2324670T3 (el)
HK (1) HK1084895A1 (el)
IL (1) IL174660A (el)
MX (1) MXPA06003656A (el)
NO (1) NO335933B1 (el)
NZ (1) NZ546692A (el)
PL (1) PL1667666T3 (el)
PT (1) PT1667666E (el)
SI (1) SI1667666T1 (el)
WO (1) WO2005032526A1 (el)
ZA (1) ZA200603504B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
ATE359777T1 (de) * 2002-12-17 2007-05-15 Abbott Gmbh & Co Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
US8026281B2 (en) * 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
JP2008531509A (ja) * 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
EP2037888A2 (en) * 2006-06-26 2009-03-25 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
FR2940118B1 (fr) * 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US20100166857A1 (en) * 2008-12-30 2010-07-01 Dong Yan Pharmaceutical dosage forms and methods of manufacturing same
WO2010092925A1 (ja) * 2009-02-12 2010-08-19 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
CN101502497B (zh) * 2009-03-06 2010-11-10 安徽省药物研究所 非诺贝特药物组合物
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions
EP2846778B1 (en) * 2012-05-07 2018-04-25 Bristol-Myers Squibb Holdings Ireland Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
CA2877901A1 (en) * 2012-06-25 2014-01-03 Mylan, Inc. Fenofibrate formulation
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) * 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
US10278914B2 (en) 2015-08-13 2019-05-07 Coty Inc. Formulation and method for promoting cutaneous uptake of molecular oxygen by skin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
CH543472A (fr) 1969-01-31 1973-10-31 Orchimed Sa Procédé pour la préparation d'acides phénoxyalcoyl-carboxyliques
GB1579818A (en) 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0012523B2 (en) 1978-11-20 1988-02-03 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
US4344934A (en) 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
FR2494112B1 (el) 1980-11-19 1986-01-10 Laruelle Claude
GB8414220D0 (en) 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8414221D0 (en) 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
ATE105710T1 (de) 1990-07-02 1994-06-15 Boehringer Mannheim Gmbh Verfahren zur herstellung geformter, verpresster dosiseinheiten mit retardierter freisetzung und entsprechende dosiseinheit.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5223268A (en) 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DK0519144T3 (da) 1991-06-21 1998-03-23 Ilsan Ilac Ve Hammaddeleri San Ny galenisk proces for omeprazol indeholdende pellets
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5480330A (en) * 1994-10-04 1996-01-02 Outboard Marine Corporation Marine propulsion pump with two counter rotating impellers
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
DE19608750A1 (de) 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
PL330864A1 (en) 1996-06-28 1999-06-07 Schering Corp Orally administered composition containing antimycotic compounds of triazole
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
AU2005299A (en) * 1997-12-20 1999-07-12 Genencor International, Inc. Fluidized bed matrix granule
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US6368620B2 (en) 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
JP2001089373A (ja) * 1999-09-24 2001-04-03 Tanabe Seiyaku Co Ltd 経口投与製剤
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
AU2001262945B2 (en) * 2000-09-20 2006-02-02 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US8026281B2 (en) 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
ATE398878T1 (de) * 2006-04-20 2008-07-15 Alcatel Lucent Verfahren und vorrichtung für effiziente gewichtete und gerechte datenüberwachung

Also Published As

Publication number Publication date
IL174660A0 (en) 2006-08-20
CA2540235C (en) 2012-07-17
BRPI0414860B1 (pt) 2019-01-15
DK1667666T3 (da) 2009-06-22
EP2000133A2 (en) 2008-12-10
NZ546692A (en) 2010-03-26
WO2005032526A1 (en) 2005-04-14
ZA200603504B (en) 2007-04-25
NO335933B1 (no) 2015-03-30
US7863331B2 (en) 2011-01-04
EP1667666A1 (en) 2006-06-14
JP5490354B2 (ja) 2014-05-14
IL174660A (en) 2011-10-31
ES2324670T3 (es) 2009-08-12
EP2000133A3 (en) 2009-05-13
US20100112049A1 (en) 2010-05-06
US20040137055A1 (en) 2004-07-15
BRPI0414860A (pt) 2006-11-28
PL1667666T3 (pl) 2009-09-30
EP1667666B1 (en) 2009-04-15
KR101150235B1 (ko) 2012-07-05
AU2004277757A1 (en) 2005-04-14
HK1084895A1 (en) 2006-08-11
BRPI0414860B8 (pt) 2021-05-25
ATE428408T1 (de) 2009-05-15
DE602004020641D1 (de) 2009-05-28
MXPA06003656A (es) 2006-06-05
EP1667666B9 (en) 2009-10-21
SI1667666T1 (sl) 2009-08-31
KR20060123728A (ko) 2006-12-04
PT1667666E (pt) 2009-06-15
NO20061960L (no) 2006-05-03
CN100544712C (zh) 2009-09-30
JP2007507486A (ja) 2007-03-29
CA2540235A1 (en) 2005-04-14
AU2004277757B2 (en) 2010-03-04
CN1863518A (zh) 2006-11-15
US8529952B2 (en) 2013-09-10

Similar Documents

Publication Publication Date Title
CY1109929T1 (el) Φαρμακευτικη συνθεση η οποια περιεχει φενοφιμπρατη και μεθοδος για την παρασκευη της
HRP20120136T1 (hr) Imunogeni pripravak koji sadrži adjuvans
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
AR057422A1 (es) Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
RS50035B (sr) Farmaceutska kompozicija koja sadrži fenofibrat i postupak za njeno dobijanje
AR018673A1 (es) Derivados de 1,3-oxazolina y 1,3-tiazolina; procedimiento para su preparacion, composicion fitoprotectora, fungicida, insecticida acaricida nematocida y para la aplicacion en la proteccion de la madera o como agente de conservacion en masas de ...
JP2007532697A5 (el)
NO20062050L (no) Terapeutiske kombinasjoner av antihypertensive og antiangiogene midler
BRPI0914902B8 (pt) Composição farmacêutica para uso no tratamento de mal de parkinson
AR054609A1 (es) Composiciones similares a batido que contienen agente de solidificacion y metodos para prepararlas y usarlas
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BRPI0407667A (pt) metabólitos de estradiol para o tratamento de hipertensão pulmonar
BRPI0413474A (pt) uso de interferon e ribavirina e kit para uso no tratamento de infecções virais
DK1305057T3 (da) Mikropartikelformig biomaterialesammensætning af hyaluronsyre til medicinsk anvendelse
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BRPI0409387B8 (pt) complexo de alvejamento de tecido mole de tório-227 e um agente complexante, uso do mesmo, composição farmacêutica, método para a formação de um complexo, e, kit para uso em um método para o tratamento de doença de tecido mole em um indivíduo mamífero
BR0210063A (pt) Composição estável e uso da mesma
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
EP1270000A3 (en) Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
WO2004089969A3 (en) Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
DK50092D0 (da) Praeparat til behandling af cryptosporidiose